Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib Plus Anti-HER2 and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer
NCT07610720Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Started Jun 2026; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07610720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610720.